July 2 2021

When patients with locally advanced or metastatic soft tissue sarcoma do not respond to standard chemotherapy, they face a difficult situation.

The frontline combination of camrelizumab and chemotherapy resulted in improved overall survival and progression-free survival and a manageable safety profile compared with placebo plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.

Adjuvant treatment with atezolizumab led to a significant improvement in disease-free survival versus supportive care in patients with PD-L1–positive non–small cell lung cancer.

Patients who recived olaparib after a median follow-up of 2.5 years revealed a 42% reduction in invasive disease–free survival, including local and metastatic recurrence of breast cancer, other new cancers, and death due to any cause.

IMPROVED OVERALL and progres-sion-free survival rates were reported for the maintenance frontline combination of avelumab and best supportive care versus BSC alone across subgroups of patients with advanced urothelial cancer.

In patients with progressive prostate-specific membrane antigen positive metastatic castration-resistant prostate cancer receiving treatment in the phase 3 VISION trial, the addition of the targeted radioligand therapy 177Lu-PSMA-617 to standard of care led to a nearly 40% reduction in the risk of death versus SOC alone.

Immune-checkpoint inhibitor therapy, involving anti–CTLA-4 and anti–PD-1/ PD-L1 agents, has transformed the treatment of melanoma. Nonetheless, even with combination anti–PD-1 and anti–CTLA-4 therapy, nearly 50% of patients die of their disease at 5 years.